Valneva awaited on regulatory filing for Lyme vaccine authorization

Investors are tracking Valneva for the submission timeline of its Lyme vaccine marketing authorization application.

Published 13sem1 source

≈ 21sSpeed

The fact

This regulatory approval represents a major milestone for the French biotech and its market valuation.

The timing of the filing with health authorities remains a key market question.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on April 17, 2026